Cargando…
Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy
Pyroptosis is a highly specific type of inflammatory programmed cell death that is mediated by Gasdermine (GSDM). It is characterized by inflammasome activation, caspase activation, and cell membrane pore formation. Diabetic cardiomyopathy (DCM) is one of the leading diabetic complications and is a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959892/ https://www.ncbi.nlm.nih.gov/pubmed/35355717 http://dx.doi.org/10.3389/fphar.2022.842313 |
_version_ | 1784677263185281024 |
---|---|
author | Cai, Zhengyao Yuan, Suxin Luan, Xingzhao Feng, Jian Deng, Li Zuo, Yumei Li, Jiafu |
author_facet | Cai, Zhengyao Yuan, Suxin Luan, Xingzhao Feng, Jian Deng, Li Zuo, Yumei Li, Jiafu |
author_sort | Cai, Zhengyao |
collection | PubMed |
description | Pyroptosis is a highly specific type of inflammatory programmed cell death that is mediated by Gasdermine (GSDM). It is characterized by inflammasome activation, caspase activation, and cell membrane pore formation. Diabetic cardiomyopathy (DCM) is one of the leading diabetic complications and is a critical cause of fatalities in chronic diabetic patients, it is defined as a clinical condition of abnormal myocardial structure and performance in diabetic patients without other cardiac risk factors, such as hypertension, significant valvular disease, etc. There are no specific drugs in treating DCM despite decades of basic and clinical investigations. Although the relationship between DCM and pyroptosis is not well established yet, current studies provided the impetus for us to clarify the significance of pyroptosis in DCM. In this review, we summarize the recent literature addressing the role of pyroptosis and the inflammasome in the development of DCM and summary the potential use of approaches targeting this pathway which may be future anti-DCM strategies. |
format | Online Article Text |
id | pubmed-8959892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89598922022-03-29 Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy Cai, Zhengyao Yuan, Suxin Luan, Xingzhao Feng, Jian Deng, Li Zuo, Yumei Li, Jiafu Front Pharmacol Pharmacology Pyroptosis is a highly specific type of inflammatory programmed cell death that is mediated by Gasdermine (GSDM). It is characterized by inflammasome activation, caspase activation, and cell membrane pore formation. Diabetic cardiomyopathy (DCM) is one of the leading diabetic complications and is a critical cause of fatalities in chronic diabetic patients, it is defined as a clinical condition of abnormal myocardial structure and performance in diabetic patients without other cardiac risk factors, such as hypertension, significant valvular disease, etc. There are no specific drugs in treating DCM despite decades of basic and clinical investigations. Although the relationship between DCM and pyroptosis is not well established yet, current studies provided the impetus for us to clarify the significance of pyroptosis in DCM. In this review, we summarize the recent literature addressing the role of pyroptosis and the inflammasome in the development of DCM and summary the potential use of approaches targeting this pathway which may be future anti-DCM strategies. Frontiers Media S.A. 2022-03-07 /pmc/articles/PMC8959892/ /pubmed/35355717 http://dx.doi.org/10.3389/fphar.2022.842313 Text en Copyright © 2022 Cai, Yuan, Luan, Feng, Deng, Zuo and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cai, Zhengyao Yuan, Suxin Luan, Xingzhao Feng, Jian Deng, Li Zuo, Yumei Li, Jiafu Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy |
title | Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy |
title_full | Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy |
title_fullStr | Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy |
title_full_unstemmed | Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy |
title_short | Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy |
title_sort | pyroptosis-related inflammasome pathway: a new therapeutic target for diabetic cardiomyopathy |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959892/ https://www.ncbi.nlm.nih.gov/pubmed/35355717 http://dx.doi.org/10.3389/fphar.2022.842313 |
work_keys_str_mv | AT caizhengyao pyroptosisrelatedinflammasomepathwayanewtherapeutictargetfordiabeticcardiomyopathy AT yuansuxin pyroptosisrelatedinflammasomepathwayanewtherapeutictargetfordiabeticcardiomyopathy AT luanxingzhao pyroptosisrelatedinflammasomepathwayanewtherapeutictargetfordiabeticcardiomyopathy AT fengjian pyroptosisrelatedinflammasomepathwayanewtherapeutictargetfordiabeticcardiomyopathy AT dengli pyroptosisrelatedinflammasomepathwayanewtherapeutictargetfordiabeticcardiomyopathy AT zuoyumei pyroptosisrelatedinflammasomepathwayanewtherapeutictargetfordiabeticcardiomyopathy AT lijiafu pyroptosisrelatedinflammasomepathwayanewtherapeutictargetfordiabeticcardiomyopathy |